Targeted cancer therapy takes another step forward with evidence that patients harboring specific genetic alterations in their tumors may benefit from precision medicine approaches. The MET gene, when amplified in gastric and gastroesophageal junction cancers, creates vulnerability that newer therapeutic agents can exploit.
The phase 2 clinical trial evaluated savolitinib, a selective MET tyrosine kinase inhibitor, specifically in patients whose tumors showed MET gene amplification. This biomarker-driven approach represents a shift from one-size-fits-all chemotherapy toward treatments matched to tumor genetics. The trial included both exploratory and pivotal phases, with results presented at the 2026 ASCO Annual Meeting demonstrating what researchers termed "promising clinical efficacy" in this molecularly defined patient population.
This development reflects the broader evolution of oncology toward precision medicine, where genetic profiling guides treatment selection. MET amplification occurs in roughly 2-5% of gastric cancers, creating a relatively small but clearly defined patient group. Previous attempts to target MET broadly in unselected populations showed limited success, highlighting the importance of proper patient selection based on molecular markers.
The promising results warrant cautious optimism rather than celebration. Phase 2 trials, while encouraging, represent intermediate steps in drug development. Key questions remain about durability of response, optimal patient selection criteria, and how savolitinib might integrate with existing treatment regimens. The gastric cancer landscape has seen multiple promising agents fail in later-stage trials, emphasizing the need for larger confirmatory studies. However, the targeted approach based on MET amplification provides a more rational foundation than previous broad-spectrum strategies.